Temozolomide

Generic Name
Temozolomide
Brand Names
Temodar, Temomedac, Temodal, Temozolomide Sun, Temozolomide Accord, Temozolomide Teva
Drug Type
Small Molecule
Chemical Formula
C6H6N6O2
CAS Number
85622-93-1
Unique Ingredient Identifier
YF1K15M17Y
Background

Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably ...

Indication

Temozolomide is indicated in adult patients for the treatment of newly diagnosed glioblastoma concomitantly with radiotherapy and for use as maintenance treatment thereafter. It is also indicated for the treatment of refractory anaplastic astrocytoma in adult patients or adjuvant therapy for adults with newly diagnosed anaplastic astrocytoma.

Associated Conditions
Advanced Melanoma, High Grade Glioma: Glioblastoma (GBM), Primary Central Nervous System Lymphoma, Refractory Ewing Sarcoma, Refractory Neuroblastoma, Soft Tissue Sarcoma, Advanced Neuroendocrine tumor, Newly diagnosed Anaplastic Astrocytoma (AA), Refractory Anaplastic astrocytoma, Refractory, advanced Mycosis fungoides, Refractory, advanced Sezary Syndrome
Associated Therapies
-
Clinical Trials
Related News

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

First Posted Date
2023-08-28
Last Posted Date
2023-09-21
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
30
Registration Number
NCT06013618
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

NBM-BMX Administered Orally to Patients with Solid Tumors or Newly Diagnosed Glioblastoma

First Posted Date
2023-08-25
Last Posted Date
2024-11-14
Lead Sponsor
Novelwise Pharmaceutical Corporation
Target Recruit Count
79
Registration Number
NCT06012695
Locations
🇨🇳

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan

🇨🇳

Hualien Tzu Chi Hospital, Hualien City, Taiwan

🇨🇳

Taichung Veterans General Hospital, Taichung City, Taiwan

and more 2 locations

A Phase Ib Trial of Eribulin in Combination with Irinotecan and Temozolamide in Children with Relapsed or Refractory Solid Tumors

First Posted Date
2023-08-23
Last Posted Date
2024-10-04
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
48
Registration Number
NCT06006273
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

First Posted Date
2023-08-21
Last Posted Date
2024-12-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
105
Registration Number
NCT05999994
Locations
🇧🇪

UCL- Saint Luc, Bruxelles, Belgium

🇫🇷

Institut Curie, Paris, France

🇳🇱

Prinses Maxima Centrum, Utrecht, Netherlands

and more 63 locations

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

First Posted Date
2023-06-13
Last Posted Date
2024-11-25
Lead Sponsor
CarThera
Target Recruit Count
560
Registration Number
NCT05902169
Locations
🇫🇷

Hôpital Neurologique Pierre Wertheimer, Bron, France

🇫🇷

Hôpital de La Timone, Marseille, France

🇫🇷

Hôpital de la Pitié-Salpêtrière, Paris, France

and more 25 locations

Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT

First Posted Date
2023-06-09
Last Posted Date
2023-09-05
Lead Sponsor
Ruijin Hospital
Target Recruit Count
29
Registration Number
NCT05896007
Locations
🇨🇳

Ruijin Hospital, Shanghai, Shanghai, China

A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL

Phase 2
Recruiting
Conditions
Pheochromocytoma
Paraganglioma
Interventions
Drug: Temozolomide
First Posted Date
2023-06-01
Last Posted Date
2023-06-01
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
20
Registration Number
NCT05885386
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, China

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

First Posted Date
2023-05-30
Last Posted Date
2024-04-18
Lead Sponsor
Orbus Therapeutics, Inc.
Target Recruit Count
66
Registration Number
NCT05879367
Locations
🇺🇸

Duke University, Durham, North Carolina, United States

🇺🇸

The Cleveland Clinic, Cleveland, Ohio, United States

🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

and more 5 locations

Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study

First Posted Date
2023-03-23
Last Posted Date
2024-08-29
Lead Sponsor
Mayo Clinic
Target Recruit Count
170
Registration Number
NCT05781321
Locations
🇺🇸

Mayo Clinic Health Systems-Mankato, Mankato, Minnesota, United States

🇺🇸

Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota, United States

🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

and more 5 locations

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

First Posted Date
2023-03-13
Last Posted Date
2024-12-20
Lead Sponsor
Debiopharm International SA
Target Recruit Count
132
Registration Number
NCT05765812
Locations
🇺🇸

New York University Langone Medical Center, New York, New York, United States

🇺🇸

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 7 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy